Stock Taper
CINGW
CINGULATE INC.
NASDAQ
$0.01
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$76.31 K
52w High$0.04
52w Low$0.01
Dividend Yield
Frequency
P/E
Volume101
Shares Out.6.75M

COMPANY

LEADERSHIP

Shane J. Schaffer
CHIEF EXECUTIVE
Shane J. Schaffer

COMPENSATION 2026

Salary$479,527
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,896,525

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 8, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
14

UPCOMING EARNINGS

DateNov 18, 2026
DayWednesday
Rev. Est.$540.00K
NOV
18
WED

PRICE

$0.01 ▲ UP 0.00% (+$0.00)
$0.01$0.01$0.01$0.01$0.01$0.01$0.0112:20 PM12:20 PM12:20 PM12:20 PM12:20 PM12:20 PM12:21 PM0.01

About Cingulate Inc.

https://www.cingulate.com ↗

Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for CNS and neurobiological disorders, including ADHD and anxiety, with lead candidates CTx-1301, CTx-1302, and CTx-2103.

INDUSTRY

Biotechnology

A PRODUCT CINGULATE INC. IS KNOWN FOR

CTx-1301
CTx-1301

CTx-1301, Cingulate’s lead once-daily ADHD treatment using the proprietary PTR™ platform, is in late-stage development with an FDA action date of May 31, 2026.

COMPETITORS

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

OFFICER: EVP AND CFO
Callahan Jennifer L.
Purchase · 19.8K shares
2026-07-16
OFFICER: EVP AND CHIEF MEDICAL OFFICER
Brams Matthew
Purchase · 26.4K shares
2026-07-16
OFFICER: EVP AND CSO
Silva Raul R.
Purchase · 26.4K shares
2026-07-16
DIRECTOR
Hargroves Thomas Jeffrey
Purchase · 20.0K shares
2026-07-16

SECTORS PEERS

PEERPRICE
TVGN$7.34COMPARE
COCP$1.13COMPARE
PHIO$1.08COMPARE
INAB$1.20COMPARE
KALA$0.51COMPARE
BOLT$3.90COMPARE
EVGN$0.54COMPARE
APVO$1.74COMPARE